CTOs on the Move

Norbrook

www.norbrook.com

 
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world.    The company is very active in both medical and veterinary products.    Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.norbrook.com
  • 9733 Loiret Boulevard
    Lenexa, KS USA 66219
  • Phone: 913.599.5777

Executives

Name Title Contact Details

Similar Companies

RSP Nutrition

RSP Nutrition is a company that makes premium nutritional supplements that inspire customers to live healthy, active lifestyles and achieve their fitness goals.

JASPER CLINICAL RandD INC

JASPER CLINICAL R&D INC is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cubist Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.